Abstract
ObjectivesTo compare the performance of the PRECISE scoring system against several MRI-derived delta-radiomics models for predicting histopathological prostate cancer (PCa) progression in patients on active surveillance (AS).MethodsThe study included AS patients with biopsy-proven PCa with a minimum follow-up of 2 years and at least one repeat targeted biopsy. Histopathological progression was defined as grade group progression from diagnostic biopsy. The control group included patients with both radiologically and histopathologically stable disease. PRECISE scores were applied prospectively by four uro-radiologists with 5–16 years’ experience. T2WI- and ADC-derived delta-radiomics features were computed using baseline and latest available MRI scans, with the predictive modelling performed using the parenclitic networks (PN), least absolute shrinkage and selection operator (LASSO) logistic regression, and random forests (RF) algorithms. Standard measures of discrimination and areas under the ROC curve (AUCs) were calculated, with AUCs compared using DeLong’s test.ResultsThe study included 64 patients (27 progressors and 37 non-progressors) with a median follow-up of 46 months. PRECISE scores had the highest specificity (94.7%) and positive predictive value (90.9%), whilst RF had the highest sensitivity (92.6%) and negative predictive value (92.6%) for predicting disease progression. The AUC for PRECISE (84.4%) was non-significantly higher than AUCs of 81.5%, 78.0%, and 80.9% for PN, LASSO regression, and RF, respectively (p = 0.64, 0.43, and 0.57, respectively). No significant differences were observed between AUCs of the three delta-radiomics models (p-value range 0.34–0.77).ConclusionsPRECISE and delta-radiomics models achieved comparably good performance for predicting PCa progression in AS patients.Key Points• The observed high specificity and PPV of PRECISE are complemented by the high sensitivity and NPV of delta-radiomics, suggesting a possible synergy between the two image assessment approaches.• The comparable performance of delta-radiomics to PRECISE scores applied by expert readers highlights the prospective use of the former as an objective and standardisable quantitative tool for MRI-guided AS follow-up.• The marginally superior performance of parenclitic networks compared to conventional machine learning algorithms warrants its further use in radiomics research.
Highlights
Prostate cancer (PCa) is the second commonest and the fifth deadliest male cancer worldwide [1]
The study included consecutive patients with biopsy-proven PCa enrolled on the local active surveillance (AS) programme with a minimum follow-up of 2 years, with their first and last 3T magnetic resonance imaging (MRI) scans performed on the same magnet, and at least one repeat targeted biopsy performed within a year of the last MRI
No significant differences were reported between AUCs of the three delta-radiomics models (p-value range 0.342–0.768). This proof-of-concept study investigates the comparative performance of the MRI-derived PRECISE scoring system applied in routine clinical practice by expert uro-radiologists versus three delta-radiomics models developed using the parenclitic networks, least absolute shrinkage and selection operator (LASSO) regression, and random forests machine learning methods
Summary
Prostate cancer (PCa) is the second commonest and the fifth deadliest male cancer worldwide [1]. Whilst tumour progression is the expected natural outcome of AS, there is a lack of objective non-invasive diagnostic tools enabling continuous re-evaluation of the risk of PCa progression. If proven accurate and standardisable, such tools could help clinicians make more informed decisions on the need for switching to radical treatment without repeat biopsies, thereby reducing the risk of associated complications and costs to healthcare systems. At this stage, this unmet clinical need is partially addressed by the increasing reliance on magnetic resonance imaging (MRI) as an integral part of AS follow-up [12,13,14,15].
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have